Published in J Invest Dermatol on September 04, 2013
PHIPing out: a genetic basis for tumor ulceration. J Invest Dermatol (2014) 0.75
A CRISPR/Cas9 Functional Screen Identifies Rare Tumor Suppressors. Sci Rep (2016) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
On the origin of cancer cells. Science (1956) 49.55
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol (1996) 15.20
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A (2005) 3.05
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer (2003) 2.20
Control of autofluorescence of archival formaldehyde-fixed, paraffin-embedded tissue in confocal laser scanning microscopy (CLSM). J Histochem Cytochem (2001) 2.08
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest (2012) 1.85
Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature (2000) 1.84
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol (2006) 1.68
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci U S A (1997) 1.61
Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res (2009) 1.40
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer (2011) 1.28
Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A (2006) 1.27
Osteopontin as a molecular prognostic marker for melanoma. Cancer (2008) 1.20
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol (2002) 1.12
A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol (2003) 1.07
Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway. J Biol Chem (2002) 1.06
Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res (2004) 1.06
Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol (2006) 1.02
Fluorescence in situ Hybridization (FISH). Curr Protoc Cell Biol (2004) 1.02
Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma. Nucl Med Commun (2007) 1.02
Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol (2009) 1.01
A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res (2009) 1.01
Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg (2010) 0.96
Targeting NADPH oxidases for the treatment of cancer and inflammation. Cell Mol Life Sci (2012) 0.96
Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. Proc Natl Acad Sci U S A (2012) 0.82
Probe labeling and fluorescence in situ hybridization. Curr Protoc Cytom (2001) 0.79
Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma. Am J Surg Pathol (2011) 0.77